# US 2022/0031866 A1 · Gene therapy vectors for treating heart disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031866 A1
- Document ID: US20220031866A1
- Status: Published application
- Kind: A1
- Application number: 17/507,362
- Filed: 2021-10-21
- Published: 2022-02-03
- Earliest claimed: 2020-02-13
- Assignees: Tenaya Therapeutics, Inc.
- Applicants: Tenaya Therapeutics, Inc.
- Inventors: Laura LOMBARDI
- Web page: https://patentgrep.com/patent/US20220031866A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 14/4716: {Muscle proteins, e.g. myosin, actin}
- A01K 67/0276: Knock-out vertebrates
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 15/86: Viral vectors
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0375: Animal model for cardiovascular diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 15/8645: {Adeno-associated virus}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present disclosure provides methods and compositions useful for the treatment or prevention of heart disease. In particular, the present disclosure provides a vector comprising a modified troponin promoter operatively linked to a therapeutic gene product for the treatment or prevention of heart disease, e.g., cardiomyopathy. The gene product may be MYBPC3. The disclosure also provides recombinant adeno-associated virus (rAAV) virions, rAAV viral genomes, and expression cassettes and pharmaceutical compositions thereof. The disclosure further provides methods for treating a disease or disorder, such as heart disease.

## Claims

### Claim 1

A recombinant adeno-associated virus (rAAV) virion, comprising a vector genome comprising an expression cassette comprising a polynucleotide encoding myosin binding protein C (MYBPC3) operatively linked to a promoter, the expression cassette flanked by a 5′ inverted terminal repeat (ITR) and a 3′ ITR; wherein the vector genome comprises at most 4.8 kilobase pairs (kbp).

### Claim 2 (depends on 1)

The rAAV virion of claim 1, wherein the promoter is a cardiac troponin T promoter.

### Claim 3 (depends on 2)

The rAAV virion of claim 2, wherein the cardiac troponin T promoter comprises about 400 bp.

### Claim 4 (depends on 2)

The rAAV virion of claim 2, wherein the cardiac troponin T promoter comprises about 400 bp and wherein the cardiac troponin T promoter shares at least 90% identity to the polynucleotide sequence of SEQ ID NO: 3.

### Claim 5 (depends on 1)

The rAAV virion of claim 1, wherein MYBPC3 shares at least 90% identity to the amino acid sequence of SEQ ID NO: 103.

### Claim 6 (depends on 1)

The rAAV virion of claim 1, wherein the polynucleotide encoding MYBPC3 shares at least 80% identity to the polynucleotide sequence of SEQ ID NO: 86.

### Claim 7 (depends on 1)

The rAAV virion of claim 1, wherein the vector genome comprises at most 4.7 kbp.

### Claim 8 (depends on 1)

The rAAV virion of claim 1, wherein the vector genome comprises 4.7 kbp,

### Claim 9 (depends on 1)

The rAAV virion of claim 1, wherein the 5′ ITR comprises a sequence that shares 95% identity to the polynucleotide sequence of SEQ ID NO: 96; and the 3′ ITR comprises a sequence that shares at least 95% identity to the polynucleotide sequence of SEQ ID NO: 97.

### Claim 10 (depends on 2)

The rAAV virion of claim 2, wherein the cardiac troponin T promoter shares at least 80% identity to the polynucleotide sequence of SEQ ID NO: 3.

### Claim 11 (depends on 2)

The rAAV virion of claim 2, wherein the cardiac troponin T promoter shares at least 95% identity to the polynucleotide sequence of SEQ ID NO: 3.

### Claim 12 (depends on 1)

The rAAV virion of claim 1, wherein the expression cassette shares at least 80% identity to the polynucleotide sequence of SEQ ID NO: 95.

### Claim 13 (depends on 1)

The rAAV virion of claim 1, wherein the expression cassette shares at least 90% identity to the polynucleotide sequence of SEQ ID NO: 95.

### Claim 14 (depends on 1)

The rAAV virion of claim 1, wherein the vector genome shares at least 80% identity to the polynucleotide sequence of SEQ ID NO: 102.

### Claim 15 (depends on 1)

The rAAV virion of claim 1, wherein the vector genome shares at least 90% identity to the polynucleotide sequence of SEQ ID NO: 102.

### Claim 16 (depends on 1)

The rAAV virion of claim 1, wherein the rAAV virion is a serotype AAV9 virion.
